BioPharma Dive1 min read
saveFDA again turns back Capricor Duchenne cell therapy
In an unusual statement, the FDA accused Capricor of “serious data integrity violations” that compromised its study findings and led to deramiocel’s second rejection since 2025.
comments(0)
5-min edit window · permanent after that